Support

Support Options

Submit a Support Ticket

 

BME 695N Lecture 20: GMP and issues of quality control manufacture of nanodelivery systems

By James Leary

Basic Medical Sciences and Biomedical Engineering, Purdue University, West Lafayette, IN

Published on

Abstract

Outline:
  1. Overview
    1. What does cGMP mean?
    2. Why GMP? Controlling processes means more predictable outcomes…
    3. Enforcement
    4. What can be learned from the semi-conductor industry clean-room and manufacturing?
    5. What doesn’t fit this paradigm?
  2. cGMP-level manufacturing
    1. Predictable methods lead to predictable products
    2. The CFR (Code of Federal Regulations) sections on GMPs
    3. What is covered under cGMP?
  3. Bionanomanufacturing
    1. So what is special about biomanufacturing?
    2. Nano-clean water necessary for nano-pharmaceuticals
    3. Contaminants at the nano-level
    4. Can you scale up the process?
  4. Some quality control issues – how to test
    1. Correctness of size – size matters!
    2. Composition – atomic level analyses
    3. Monodispersity versus agglomeration
    4. Order and correctness of layers
    5. Correctness of zeta potentials
    6. Does the nanomedical system contain the correct payload?
    7. Targeting (and mis-targeting) specificity and sensitivity

References

Cite this work

Researchers should cite this work as follows:

  • James Leary (2007), "BME 695N Lecture 20: GMP and issues of quality control manufacture of nanodelivery systems," http://nanohub.org/resources/3529.

    BibTex | EndNote

Time

Location

Biomedical Engineering Building, Rm 1083

Tags

nanoHUB.org, a resource for nanoscience and nanotechnology, is supported by the National Science Foundation and other funding agencies. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation.